CD47 and neoplasm: However, in PBTs the limited presence of tumour-associated antigens (TAAs) due to the low TMB and the increased release of CD47 often detected in MYC-amplified tumours that reduce phagocytosis lead to low levels of antigen presentation and, consequently, lower anti-tumour immunity [33].